{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T13:30:31Z","timestamp":1793539831711,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109621","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:22:23Z","timestamp":1788621743000},"page":"109621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-0221","authenticated-orcid":false,"given":"Anouk H.","family":"Eijkelboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1321-3969","authenticated-orcid":false,"given":"Bas J.M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-7902","authenticated-orcid":false,"given":"Daphne W.","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz M.N.H.","family":"Schramel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-7047","authenticated-orcid":false,"given":"Ronald A.M.","family":"Damhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter H.","family":"van Geffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109621_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2026.109621_b0010","unstructured":"Netherlands Comprehensive Cancer Organisation (IKNL), Incidence by year, 2025. https:\/\/nkr-cijfers.iknl.nl\/viewer\/incidentie-per-jaar?language=en_GB&viewerId=1b3d6d5b-75b9-44aa-88f0-e18e85a25a70. (Accessed 03-09-2025 2025)."},{"key":"10.1016\/j.lungcan.2026.109621_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the phase III IMpower133 study and the phase III IMbrella a extension study","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109621_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109621_b0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109621_b0030","unstructured":"NVMO-commissie BOM, Durvalumab met chemotherapie als eerstelijnsbehandeling voor \u2018extensive stage\u2019 kleincellig longcarcinoom, 2021, p. 4."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109621_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011258","article-title":"Cancer immunotherapy clinical trials to support urgently needed access in low-and middle-income countries: a report from the SITC global access and impact committee","volume":"13","author":"Dent","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109621_b0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.lungcan.2019.03.028","article-title":"Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017","volume":"131","author":"Lattuca-Truc","year":"2019","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109621_b0045","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/curroncol28040243","article-title":"Patterns of relapse in small cell lung cancer: competing risks of thoracic versus CNS relapse","volume":"28","author":"Ellis","year":"2021","journal-title":"Curr. Oncol."},{"issue":"10212","key":"10.1016\/j.lungcan.2026.109621_b0050","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109621_b0055","first-page":"1","article-title":"NCCN guidelines for patients - Small Cell","author":"Network","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109621_b0060","unstructured":"Federatie Medisch Specialisten, Kleincellig longcarcinoom, 2025. https:\/\/richtlijnendatabase.nl\/richtlijn\/kleincellig_longcarcinoom\/startpagina_kleincellig_longcarcinoom.html. (Accessed 08-09-2025 2025)."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109621_b0065","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109621_b0070","article-title":"Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: a nationwide Netherlands registry study in small cell lung cancer patients (CACIS)","volume":"116042","author":"Houda","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109621_b0075","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamaoncol.2015.3113","article-title":"Performance status in patients with cancer","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109621_b0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jtho.2023.09.1446","article-title":"Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage SCLC in the era of immunotherapy","volume":"19","author":"Torasawa","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109621_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005762","article-title":"Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib","volume":"4","author":"Griebsch","year":"2014","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109621_b0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0643","article-title":"Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lungcan.2026.109621_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1154685","article-title":"Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: a systematic review and Bayesian network analysis","volume":"13","author":"Shi","year":"2023","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109621_b0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000540244","article-title":"Female patients with small cell lung cancer have better survival than males with extensive but not limited disease","volume":"47","author":"Tas","year":"2024","journal-title":"Oncol. Res. Treat."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109621_b0105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/annonc\/mdp300","article-title":"The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit","volume":"21","author":"Wheatley-Price","year":"2010","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109621_b0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cllc.2011.05.008","article-title":"Small-cell lung cancer: prognostic factors and changing treatment over 15 years","volume":"13","author":"Gaspar","year":"2012","journal-title":"Clin. Lung Cancer"},{"issue":"03","key":"10.1016\/j.lungcan.2026.109621_b0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4236\/ojim.2014.43008","article-title":"Gender-related survival in different stages of lung cancer\u2014A population study over 20 years","volume":"4","author":"Svensson","year":"2014","journal-title":"Open Journal of Internal Medicine"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109621_b0120","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1111\/1759-7714.14712","article-title":"Prognostic factors for survival in extensive\u2010stage small cell lung cancer: an italian real\u2010world retrospective analysis of 244 patients treated over the last decade","volume":"13","author":"Longo","year":"2022","journal-title":"Thoracic Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109621_b0125","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1002\/cncr.24314","article-title":"Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials","volume":"115","author":"Foster","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109621_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108786","article-title":"Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer","author":"Andreas","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109621_b0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.lungcan.2019.02.026","article-title":"Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - results from the prospective German TLK cohort study","volume":"130","author":"Steffens","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109621_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107887","article-title":"Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: a large French multicenter study","volume":"194","author":"Pons-Tostivint","year":"2024","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109621_b0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.resinv.2025.03.013","article-title":"Efficacy of second line and subsequent treatments of small cell lung cancer with and without immune checkpoint inhibitor combination therapy","volume":"63","author":"Morinaga","year":"2025","journal-title":"Respir. Investig."},{"key":"10.1016\/j.lungcan.2026.109621_b0150","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241272957","article-title":"Efficacy of carboplatin\u2013etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis","volume":"16","author":"Gomez-Randulfe","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109621_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107448","article-title":"Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval\u2265 30 days and without central nervous metastases","volume":"188","author":"Peters","year":"2024","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109621_b0160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/curroncol28010036","article-title":"Real world analysis of small cell lung cancer patients: prognostic factors and treatment outcomes","volume":"28","author":"Moser","year":"2021","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109621_b0165","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109621_b0170","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.8006","article-title":"Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis","author":"Mountzios","year":"2026","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109621_b0175","article-title":"Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: a network meta-analysis","author":"Wang","year":"2026","journal-title":"Lung Cancer"},{"issue":"10495","key":"10.1016\/j.lungcan.2026.109621_b0180","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109621_b0185","unstructured":"National Comprehensive Cancer Network, Small Cell Lung Cancer, 2025."},{"key":"10.1016\/j.lungcan.2026.109621_b0190","unstructured":"European Medicines Agency, New treatment for relapsed extensive-stage small cell lung cancer, 2026. https:\/\/www.ema.europa.eu\/en\/news\/new-treatment-relapsed-extensive-stage-small-cell-lung-cancer. (Accessed 17-08-2026 2026)."},{"key":"10.1016\/j.lungcan.2026.109621_b0195","unstructured":"European Medicines Agency, Zepzelca 2026. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-zepzelca_en.pdf. (Accessed 18-08-2026 2026)."},{"key":"10.1016\/j.lungcan.2026.109621_b0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2026.1645","article-title":"First-line serplulimab in extensive-stage small cell lung cancer: secondary analysis of the ASTRUM-005 phase 3 randomized clinical trial","author":"Liu","year":"2026","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109621_b0205","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/cac2.70032","article-title":"First\u2010line serplulimab plus chemotherapy in extensive\u2010stage small\u2010cell lung cancer: Updated results and biomarker analysis from the ASTRUM\u2010005 randomized clinical trial","volume":"45","author":"Cheng","year":"2025","journal-title":"Cancer Commun."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109621_b0210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0698","article-title":"Outcomes of chemoimmunotherapy among patients with extensive-stage small cell lung cancer according to potential clinical trial eligibility","volume":"6","author":"Fujimoto","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109621_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2024.100744","article-title":"First-line chemo-immunotherapy in SCLC: outcomes of a binational real-world study","volume":"6","author":"Moliner","year":"2025","journal-title":"JTO Clinical and Research Reports"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109621_b0220","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:09:47Z","timestamp":1792037387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":44,"alternative-id":["S0169500226006823"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109621","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109621"}}